Charles River Laboratories International

Charles River Laboratories International

World Rank (Jan-05-2024)
1,471
Market Cap (Jan-05-2024)
11.492 Billion USD
World Rank (Jul-30-2023)
1,589
Market Cap (Jul-30-2023)
10.773 Billion USD
World Rank (Jan-07-2022)
1,223
Market Cap (Jan-07-2022)
16.587 Billion USD
World Rank (Jan-01-2021)
1,398
Market Cap (Jan-01-2021)
12.429 Billion USD
Company Rank in Country in 2023
Rank in USA in July-2023 is 598
Headquarters Country
USA
Nasdaq / NYSE Code
CRL
Market Cap (Mar-08-2026)
8.59
CEO
James C. Foster
Employee Count
21,400
Employee Count as of Date
As on Dec-2022
Headquarters City/State
Massachusetts
World Region
Americas
World Subregion
Northern America
Annual Revenue in USD
3,976 Million USD
Annual Operating Income in USD
650 Million USD
Annual Net Income in USD
486 Million USD
Annual Results for Period Ending
Dec-2022 ending year
Total Assets in USD
7,602 Million USD
Total Liabilities in USD
4,579 Million USD
Total Equity in USD
3,023 Million USD
Balance Sheet for Period Ending
Dec-2022 ending year
Business Sector
Healthcare
Biotechnology
Technology
HealthCare Products
Pharmaceutical
Company Website
CHARLES RIVER LABORATORIES INTERNATIONAL INC
Wikipedia
Wikipedia
Yahoo
Yahoo @ NYSE
Facebook
Facebook
Company Profile

Charles River Laboratories is a Healthcare and pharmaceutical company. The company products and services are Research animals models, genetically engineered model and services, animal health, surveillance, surgery and precondition service, generic testing services and Insourcing solutions. The headquarters is in USA.

The company currently operated 110 facilities in 20 countries.

Facts About Company

Charles River Laboratories annual revenue generated for period ending Dec-2022 was 3,976 million USD.

Charles River Laboratories annual net income generated for period ending Dec-2022 was 486 million USD.

Charles River Laboratories annual revenue generated for period ending Dec-2021 was 3,540 million USD.

Charles River Laboratories annual net income generated for period ending Dec-2021 was 391 million USD.

  • Charles River Laboratories Dec-2020 ending annual Revenue was 2,924 Million USD.
  • Total Assets as on Dec-2021 was 7,024 Million USD.
Annual Results Summary

CHARLES RIVER LABORATORIES INTERNATIONAL - Annual Results Summary - in Million USD

Year Ending:Total RevenueGross ProfitOperating IncomeNet Income
Dec-20234,1291,502617474
Dec-20223,9761,462650486
Dec-20213,5401,334589391
Dec-20202,9241,074433365
Dec-20192,621958351254
Dec-20182,266840331229
Dec-20171,858701288125
Balance Sheet Summary

Total Assets as on Dec-2023 was 8,195 Million USD.

Total Liabilities as on Dec-2023 was 4,536 Million USD.

Total Equity as on Dec-2023 was 3,658 Million USD.

Founded Year
1947
IPO Year
2000
Stock Category
S&P 500
Stock Exchange
NYSE
Company SubCategory
Top Technology Companies in USA
Top Healthcare Companies in USA
Nasdaq Sector
Health Care
Nasdaq Industry
Biotechnology: Commercial Physical & Biological Resarch

Share